Bayer Signs a Non-Exclusive Licensing Agreement with ProteoNic Biotechnology for its 2G UNic Technology

 Bayer Signs a Non-Exclusive Licensing Agreement with ProteoNic Biotechnology for its 2G UNic Technology

Bayer Signs a Non-Exclusive Licensing Agreement with ProteoNic Biotechnology for its 2G UNic Technology

Shots:

  • Bayer to get non-exclusive WW license rights to develop and commercialize its own products by using ProteoNic’s 2G UNic Technology 
  • The focus of the collaboration is to produce and enhance Bayer recombinant proteins portfolio utilizing ProteoNic’s 2G UNic Technology
  • ProteoNic’s 2G UNic Technology is a protein expression technology designed to improve cell line production levels exerting effects on recombinant protein production

 Click here to read full press release/ article | Ref: ProteoNic Biotechnology | Image: AgNewsWire

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post